Rani Therapeutics, LLC

Chapters cover methodology, executive summary, market variables, segmentation by disease, molecule, biological target, mechanism, and region, and competitive landscape.

Inflation easing and S&P 500 hitting record highs reflect a robust stock market. Oppenheimer's John Stoltzfus remains bullish on equities, projecting massive gains, including a potential 740% upside for one stock. Rani Therapeutics' RaniPill, an oral delivery system for biologics, and Ultra Clean Holdings' critical services for the semiconductor industry are highlighted as strong investment opportunities.

Dong-A ST received FDA approval for Imuldosa, a Stelara biosimilar, amidst a crowded market of approved but unlaunched biosimilars. Stelara's sales are expected to decline post-2023 patent expiry, with biosimilars like Amgen's Wezlana and Samsung Bioepis's Pyzchiva set to launch in 2025. Stelara, an IL-12/IL-23 inhibitor, treats psoriatic arthritis, Crohn’s disease, plaque psoriasis, and ulcerative colitis.